Articles & Press Releases

Recent Articles

Ken Slaw, PhD., named executive director of SVS

Press Release

CHICAGO, Illinois, May 6, 2016 –The Society for Vascular Surgery Board of Directors is pleased to announce Kenneth M. Slaw, Ph.D., as the society’s next executive director, replacing Rebecca Maron, CAE, who will retire May 30, 2016.  

Study: Too many patients don't get statins or AP after vascular surgery

Press Release

A recent review of patients who had undergone carotid, lower extremity bypass, or abdominal aortic aneurysm surgeries found that patients who received both statins and antiplatelet medications were far more likely to be alive five years later. Patients placed on both an antiplatelet agent and cholesterol medication had an adjusted 40 percent reduced risk of death at five years compared to those who received neither drug. Being on either one of these medications was also important, and was associated with an adjusted 30 percent reduced risk of death compared to those on neither medication. When considered differently, an extra 14 of every 100 patients were alive at five years if on both medications.

Rebecca Maron retiring as Executive Director of SVS

Press Release

Executive search firm conducting national search for new director

 

CHICAGO, Illinois - Society for Vascular Surgery Executive Director Rebecca Maron has announced her retirement, effective the end of May. She has served in that position for 13 years.

3 Things You Should Ask Before Surgery

Press Release

All too often patients say they are "blindsided" by unexpected outcomes of surgery. SVS member Dr. Margaret "Gretchen" Schwarze has won a prestigious PCORI grant to study ways to help patients understand what major surgery will mean to them.

SVS, APMA and SVM Publish First-Ever Guidelines for Treating Diabetic Foot

Press Release

The Society for Vascular Surgery, the American Podiatric Medical Association and the Society for Vascular Medicine collaboratively have published their first-ever set of clinical practice guidelines for treating the diabetic foot, based on a meta-analysis of the available literature. The guidelines, “The Management of the Diabetic Foot,” were developed after three years of study and were published online in late January and in print in the February 2016 edition of Journal for Vascular Surgery.

Enrollment begins for PRESERVE, large study of IVC filters

Press Release

As of mid-December, researchers have activated the first 10 medical sites and enrolled the first nine patients in a study that will determine the safety and effectiveness of inferior vena cava filters, small, cage-like devices implanted to prevent life-threatening blood clots from reaching the heart or lungs. While vein filters have been in use for years, PRESERVE (Predicting the Safety and Effectiveness of Inferior Vena Cava Filters), is the first large-scale, multispecialty, prospective clinical research trial that will evaluate their real world safety and effectiveness. The inferior vena cava is the main vessel returning blood from the lower half of the body to the heart.

Building Effective Partnerships Between Vascular Surgeons and Podiatrists in the Effective Management of Diabetic Foot Ulcers​

Article

This practice memo, a collaborative effort between the Young Physicians Programs of the American Podiatric Medical Association and the Young Surgeons Committee of the Society for Vascular Surgery, is intended to aid podiatrists and vascular surgeons in the early years of their respective careers, especially those involved in the care of patients with DFUs. During these formative years, learning how to successfully establish an inter-professional partnership is crucial in order to provide the best possible care to this important patient population.

Recent Articles

Carotid controversy: Medication alone may not eliminate stroke risk

Press Release

Recent advances in statins and other medications have led some researchers to suggest that surgical treatments for carotid stenosis should be limited to symptomatic patients – primarily those who have already had a stroke or TIA. However, a new study published in the Journal of Vascular Surgery questions whether medical therapy is a sufficient stroke-reduction strategy. In the study, only 35 percent of stroke patients were receiving both statin and antiplatelet agents prior to their event, suggesting that asymptomatic carotid disease is unrecognized in many individuals, noted lead researcher Dr. W. Darrin Clouse of Massachusetts General Hospital. “And the first manifestation of their disease,” he wrote, “could be the occurrence of a stroke.”

SVS responds to opioid crisis bill

Article

[[{"fid":"2002","view_mode":"default","fields":{"format":"default","alignment":"","field_file_image_alt_text[und][0][value]":false,"field_file_image_title_text[und][0][value]":false},"link_text":null,"type":"media","field_deltas":{"1":{"format":"default","alignment":"","field_file_image_alt_text

Please Give, Because Every Gift Matters

Article

A letter from the SVS Foundation Chair

Because …

That’s the simple – yet multifaceted — theme for our SVS Foundation Annual Report (just released and available at vsweb.org/ SVSF_Annual_Report_ 2018) and for our annual Giving Campaign.

NHLBI September 2018 Notification

Article

NHLBI has extended the combined number of years of K training support from six to eight years for the K08 and K23 grants.  This means that for clinician scientists with K08 or K23 awards they can stay on a K12 or KL2 program for up to three years and then request a five year indivi

Recent Articles

Carotid controversy: Medication alone may not eliminate stroke risk

Press Release

Recent advances in statins and other medications have led some researchers to suggest that surgical treatments for carotid stenosis should be limited to symptomatic patients – primarily those who have already had a stroke or TIA. However, a new study published in the Journal of Vascular Surgery questions whether medical therapy is a sufficient stroke-reduction strategy. In the study, only 35 percent of stroke patients were receiving both statin and antiplatelet agents prior to their event, suggesting that asymptomatic carotid disease is unrecognized in many individuals, noted lead researcher Dr. W. Darrin Clouse of Massachusetts General Hospital. “And the first manifestation of their disease,” he wrote, “could be the occurrence of a stroke.”

SVS responds to opioid crisis bill

Article

[[{"fid":"2002","view_mode":"default","fields":{"format":"default","alignment":"","field_file_image_alt_text[und][0][value]":false,"field_file_image_title_text[und][0][value]":false},"link_text":null,"type":"media","field_deltas":{"1":{"format":"default","alignment":"","field_file_image_alt_text

Please Give, Because Every Gift Matters

Article

A letter from the SVS Foundation Chair

Because …

That’s the simple – yet multifaceted — theme for our SVS Foundation Annual Report (just released and available at vsweb.org/ SVSF_Annual_Report_ 2018) and for our annual Giving Campaign.

NHLBI September 2018 Notification

Article

NHLBI has extended the combined number of years of K training support from six to eight years for the K08 and K23 grants.  This means that for clinician scientists with K08 or K23 awards they can stay on a K12 or KL2 program for up to three years and then request a five year indivi